Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025--In ...

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

Initiation of phase 1 portion of the trial planned in 2H 2026-Phase 2 portion of the trial will initiate development of the elraglusib tablet in ...
Nasdaq

Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization

Following a pivotal first half, Ainos is focused on executing across strategic pillars: Semiconductor Manufacturing with ASE - Pursue a multi-stage AI Nose rollout roadmap with ASE Technology Holding, ...
Nasdaq

Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...
Seeking Alpha

Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization

SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Ainos, Inc. (AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the completion of a 1-for-5 stock consolidation, effective at the ...